Lypovas 5/ 10/ 20 & 40 5 mg, 10 mg, 20 mg, 40 mg Tablets
PDF Leaflet Revision Date: 16 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce cardiovascular risk and treat hypercholesterolemia.
Dosage (summary)
Start at 5 mg once daily; adjust based on response, max 40 mg.
Onset of Action / Duration
Onset: 1 week, Max response: 4 weeks
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Asian patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Ciclosporin
- Gemfibrozil
- Protease inhibitors
- Fibrates
Contraindications
- Hypersensitivity to rosuvastatin
- Active liver disease
- Severe renal impairment
- Myopathy
- Pregnancy and lactation
Common side effects
- Myalgia
- Headache
- Dizziness
- Constipation
- Nausea
Counselling Points
- Report muscle pain or weakness immediately.
- Avoid alcohol.
- Use effective contraception during treatment.
Serious warnings
- Risk of myopathy/rhabdomyolysis
- Liver function monitoring required
- Caution in renal impairment
Important Disclaimer
The Lypovas 5/ 10/ 20 & 40 5 mg, 10 mg, 20 mg, 40 mg Tablets professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
